Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$26.20

-0.03 (-0.11%)

04:55
10/06/17
10/06
04:55
10/06/17
04:55

Aimmune management to meet with JMP Securities

Meeting to be held in Dallas on October 6 hosted by JMP Securities.

  • 06

    Oct

  • 17

    Oct

  • 18

    Oct

  • 06

    Nov

AIMT Aimmune
$26.20

-0.03 (-0.11%)

02/17/17
PIPR
02/17/17
NO CHANGE
Target $40
PIPR
Overweight
Piper sees Aimmune trial changes as reducing clinical risk
Piper Jaffray analyst Charles Duncan believes the Phase III change announced yesterday by Aimmune Therapeutics (AIMT) reduces clinical risk for the trial read-out, while still addressing a broad group of children and teens more broadly relative to Aimmune's "mindshare competitor" DBV Technologies (DBVT). The PALISADE Phase III primary analysis and initial BLA application will now include ages 4-17, but exclude adult patients, Duncan tells investors in a research note. Following the news, the analyst still believes Aimmune's AR101 will be approved and used in some of adult patients, but points out another trial may be required. He pushed his first AR101 sales estimate in adults back by two years to 2021 in the U.S. market and 2020 to 2022 in the E.U. market. Duncan keeps an Overweight rating on Aimmune with a $40 price target.
03/22/17
PIPR
03/22/17
NO CHANGE
Target $38
PIPR
Overweight
Piper sees Aimmune as having regulatory advantage over DBV
After hosting investor meetings with management, Piper Jaffray analyst Charles Duncan keeps an Overweight rating on Aimmune (AIMT) with a $38 price target. While regulatory visibility will increase in the next 12 months, investors today should focus on response rates for the single highest tolerated dose, or how much peanut can an allergic person tolerate in a single exposure, Duncan tells investors in a research note. The analyst sees Aimmune's AR101 as having generated "uniquely impressive results" on the two key efficacy measures relative to DBV Technologies (DBVT), including both response rates and size of highest tolerated dose. He believes investors may be overlooking catalysts for Aimmune, including up-dosing progress from the PALISADE trial prior to Phase III results around year-end.
09/12/17
JEFF
09/12/17
NO CHANGE
Target $51
JEFF
Buy
Jefferies allergist poll shows 'meaningful upside' to DBV sales estimates
Jefferies analyst Eun Yang says her firm's poll of 33 U.S. allergists indicates "meaningful upside" to her Viaskin Peanut sales estimates in the $3.5B U.S. pediatric peanut allergy market should DBV Technologies (DBVT) win approval. The poll indicates a preference for Viaskin Peanut over Aimmune Therapeutics' (AIMT) AR101 in kids with peanut allergy given its safety profile and convenience, Yang tells investors in a research note. The analyst sees a "high likelihood" of Phase 3 success for Viaskin Peanut, which DBV is expected to announce in October. On positive data, the stock could rally up to 50% from current levels, the analyst contends. She keeps a Buy rating on DBV Technologies.
10/02/17
JMPS
10/02/17
NO CHANGE
JMPS
Outperform
Parents excited about peanut allergy immunotherapy, says JMP Securities
After surveying over 60 parents with peanut allergic children, JMP Securities analyst Liisa Bayko said she was "surprised" that 85% of respondents indicated a willingness to adopt an immunotherapy to treat the allergy. While the survey group may represent a more engaged and proactive one than the larger population, Bayko said even 30% adoption would be significant as the peanut allergy market is "enormous". The analyst, who added the survey pointed to a place for both oral and epicutaneous approaches, keeps Outperform ratings on both DBV Technologies (DBVT) and Aimmune (AIMT).

TODAY'S FREE FLY STORIES

07:53
02/22/18
02/22
07:53
02/22/18
07:53
Conference/Events
STAT Plus to hold webinar »

STAT Senior Science…

AAOI

Applied Optoelectronics

$34.55

1.22 (3.66%)

07:51
02/22/18
02/22
07:51
02/22/18
07:51
Recommendations
Applied Optoelectronics analyst commentary  »

Applied Optoelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 29

    Mar

07:51
02/22/18
02/22
07:51
02/22/18
07:51
General news
Futures pointing to higher open »

Stock futures have…

07:51
02/22/18
02/22
07:51
02/22/18
07:51
Conference/Events
The FCC to hold a commission meeting »

Open Commission Meeting…

07:50
02/22/18
02/22
07:50
02/22/18
07:50
Conference/Events
Federal Reserve Bank of New York President speaks at press briefing »

New York Federal Reserve…

STMP

Stamps.com

$184.95

-5.1 (-2.68%)

07:49
02/22/18
02/22
07:49
02/22/18
07:49
Recommendations
Stamps.com analyst commentary  »

Stamps.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 23

    May

LNKD

Acquired by MSFT

07:48
02/22/18
02/22
07:48
02/22/18
07:48
Conference/Events
Detroit Economic Club to hold a breakfast meeting »

Brenda Meller, Owner and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

MCS

Marcus

$26.10

1 (3.98%)

07:48
02/22/18
02/22
07:48
02/22/18
07:48
Earnings
Marcus reports Q4 EPS $1.21, consensus 38c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    May

PHX

Panhandle Oil & Gas

07:47
02/22/18
02/22
07:47
02/22/18
07:47
Initiation
Panhandle Oil & Gas initiated  »

Panhandle Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 11

    Mar

CRM

Salesforce

$114.48

0.13 (0.11%)

07:47
02/22/18
02/22
07:47
02/22/18
07:47
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 28

    Feb

07:46
02/22/18
02/22
07:46
02/22/18
07:46
Conference/Events
FDA to co-host a workshop »

The FDA, American…

MLNX

Mellanox

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Recommendations
Mellanox analyst commentary  »

Mellanox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

RDHL

RedHill Biopharma

$6.26

0.05 (0.81%)

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Earnings
RedHill Biopharma reports Q4 EPS (26c), consensus (60c) »

Reports Q4 revenue $2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

07:43
02/22/18
02/22
07:43
02/22/18
07:43
Conference/Events
JPMorgan to hold a conference »

Korea Conference will be…

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees FY18 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Conference/Events
Deutsche Bank to hold a conference »

Indonesia Corporate Days…

ROKU

Roku

$51.10

-0.08 (-0.16%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 21

    Mar

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees Q1 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

AKBA

Akebia

$14.31

0.69 (5.07%)

, CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

07:41
02/22/18
02/22
07:41
02/22/18
07:41
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

AKBA

Akebia

$14.31

0.69 (5.07%)

CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

RDUS

Radius Health

$37.71

-0.51 (-1.33%)

TYME

Tyme Technologies

$3.37

-0.06 (-1.75%)

HCA

HCA Healthcare

$100.35

-0.65 (-0.64%)

ARAY

Accuray

MDRX

Allscripts

$13.57

0.335 (2.53%)

ABEO

Abeona Therapeutics

$11.70

0.1 (0.86%)

SGEN

Seattle Genetics

$54.11

-0.05 (-0.09%)

INSY

Insys Therapeutics

$7.93

0.34 (4.48%)

SPPI

Spectrum

$20.51

0.21 (1.03%)

SPH

Suburban Propane

$24.10

-0.2 (-0.82%)

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

DEPO

Depomed

$7.46

0.07 (0.95%)

KTWO

K2M Group

$19.09

-0.01 (-0.05%)

INOV

Inovalon

$11.68

-1.025 (-8.07%)

IMMU

Immunomedics

$16.38

0.16 (0.99%)

OVID

Ovid Therapeutics

$6.83

-0.2 (-2.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 11

    Mar

  • 14

    Mar

  • 01

    May

  • 03

    May

  • 22

    Feb

HSC

Harsco

$16.75

0.45 (2.76%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Earnings
Harsco reports Q4 EPS ex-items 20c, consensus 14c »

Reports Q4 revenue $455M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

WPC

W.P. Carey

$59.53

-0.73 (-1.21%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Hot Stocks
W.P. Carey enters into 18-year triple net lease with Astellas Institute »

W. P. Carey has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

07:40
02/22/18
02/22
07:40
02/22/18
07:40
General news
Fed's Quarles anticipates further gradual tightening »

Fed's Quarles…

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Earnings
Gibraltar Industries sees FY18 adjusted EPS $1.96-$2.08, consensus $1.81 »

Gibraltar is providing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$109.06

-1.92 (-1.73%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Recommendations
Chevron analyst commentary  »

Chevron weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRC

Brady

$38.05

0.1 (0.26%)

07:38
02/22/18
02/22
07:38
02/22/18
07:38
Earnings
Brady reports Q2 EPS 8c, may not be compared to consensus 44c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.